Skip to main content
CTSO
NASDAQ Industrial Applications And Services

Cytosorbents Discloses Deferred Executive Bonuses Due to Insufficient Liquidity

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.591
Mkt Cap
$37.068M
52W Low
$0.499
52W High
$1.39
52W Position info
18% above low
Off High info
57% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

CTSO sits 18% above its 52-week low of $0.499 on light trading volume (0.4× avg).

Summary

Cytosorbents Corp's amended 10-K reveals executive bonuses for 2024 and 2025 are deferred due to insufficient liquidity, reinforcing prior going concern warnings and highlighting severe financial challenges.


Key Events · Corporate Governance and Compliance · CTSO

  • Executive Bonuses Deferred

    Bonuses for 2024 and 2025 for named executive officers have been earned but payment is deferred until the Compensation Committee determines sufficient liquidity.

  • Reinforces Liquidity Concerns

    This disclosure explicitly confirms "insufficient liquidity," adding a concrete detail to the auditor's going concern warning and material weaknesses previously reported in the original 10-K.

  • Out-of-the-Money Equity Awards

    Directors and executives received stock options in August 2025 with an exercise price of $1.00 per share, significantly above the current stock price of $0.59.


Analysis · CTSO · Industrial Applications And Services

This 10-K/A filing, an amendment to the previously filed annual report, provides updated Part III information, including executive compensation details. The most significant disclosure is the deferral of 2024 and 2025 executive bonuses due to "insufficient liquidity." This explicitly confirms and exacerbates the financial distress indicated by the auditor's going concern warning and material weaknesses reported in the original 10-K filed on March 30, 2025. The company is also facing Nasdaq compliance issues related to its stock price, having received a 180-day extension on April 2, 2026. The out-of-the-money stock options granted to directors and executives further highlight the company's challenges. Investors should view this as a strong signal of ongoing and severe financial strain.

How filings like this one have moved

In the 30 days to Sep 13, 2026, 29.5% of the 1753 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CTSO was trading at $0.59 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $37.1M. The 52-week trading range was $0.50 to $1.39. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CTSO - Latest Insights

CTSO
Sep 09, 2026, 4:05 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $6.67
Real-time Price: $6.41 info
Change: -$0.260 (-4%) info
Market Cap: $20.199M info
CTSO
Sep 08, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.85
Real-time Price: $6.41 info
Change: Reverse Stock Split info
Market Cap: $20.199M info
CTSO
Sep 03, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $0.3616
Real-time Price: $6.41 info
Change: Reverse Stock Split info
Market Cap: $20.199M info
CTSO
Aug 14, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.3999
Real-time Price: $6.41 info
Change: Reverse Stock Split info
Market Cap: $20.199M info
CTSO
Aug 07, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.3744
Real-time Price: $6.41 info
Change: Reverse Stock Split info
Market Cap: $20.199M info